References
1. Smith SA, Auseon AJ. Chemotherapy-induced takotsubo cardiomyopathy.
Heart Fail Clin 2013;9:233-42, x.
2. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by
tyrosine kinase inhibitors. Acta Oncol 2009;48:964-70.
3. Force T, Krause DS, Van Etten RA. Molecular mechanisms of
cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer
2007;7:332-44.
4. Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-Induced
Cardiotoxicity. JACC: CardioOncology 2019;1:172-178.
5. Kunimasa K, Oka T, Hara S et al. Osimertinib is associated with
reversible and dose-independent cancer therapy-related cardiac
dysfunction. Lung Cancer 2021;153:186-192.
6. Kunimasa K, Kamada R, Oka T et al. Cardiac Adverse Events in
EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib. JACC
CardioOncol 2020;2:1-10.
7. Hirashima T, Satouchi M, Hida T et al. Osimertinib for Japanese
patients with T790M-positive advanced non-small-cell lung cancer: A
pooled subgroup analysis. Cancer Sci 2019;110:2884-2893.
8. Medina de Chazal H, Del Buono MG, Keyser-Marcus L et al. Stress
Cardiomyopathy Diagnosis and Treatment: JACC State-of-the-Art Review. J
Am Coll Cardiol 2018;72:1955-1971.
9. Templin C, Ghadri JR, Diekmann J et al. Clinical Features and
Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med
2015;373:929-38.
10. Iwakura Y, Nawa H. ErbB1-4-dependent EGF/neuregulin signals and
their cross talk in the central nervous system: pathological
implications in schizophrenia and Parkinson’s disease. Front Cell
Neurosci 2013;7:4.